Eden Prairie, MN – According to filings with the U.S. Securities and Exchange Commission, MIVI Neuroscience is raising $45,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Robert Colloton played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MIVI Neuroscience

MIVI Neuroscience, Inc. is focused on developing and commercializing superior clinical solutions for neurointerventional procedures. Our innovative product portfolio provides physicians with unique devices that are designed to improve patient outcomes by reducing complications, shortening procedure times and expanding treatment to more patients. MIVI Neuroscience, (MIVI) is an innovative medical device company that aims to achieve life-giving results for an increasing number of patients experiencing acute ischemic stroke (AIS). We accomplish this through proprietary technology designed in collaboration with physicians to vastly improve the safety and efficacy of interventional AIS therapy. .

To learn more about MIVI Neuroscience, visit http://www.mivineuro.com/

Contact:
Robert Colloton, Chief Executive Officer
952-944-3834
https://www.linkedin.com/in/bob-colloton-16565628/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved